PTC Therapeutics Inc
XMUN:BH3
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
P
|
PTC Therapeutics Inc
XMUN:BH3
|
US |
|
Fidelity National Information Services Inc
NYSE:FIS
|
US |
|
M
|
Microsoft Corp
XMUN:MSF
|
US |
|
Nongfu Spring Co Ltd
F:7NF
|
CN |
|
Health Catalyst Inc
F:2YP
|
US |
|
W
|
Weichai Power Co Ltd
OTC:WEICF
|
CN |
|
W
|
Weichai Power Co Ltd
XBER:WI4
|
CN |
|
T
|
TransAlta Corp
XMUN:TZ1
|
CA |
Wall St Price Targets
BH3 Price Targets Summary
PTC Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for BH3 is 85.53 EUR with a low forecast of 59.01 EUR and a high forecast of 117.03 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is BH3's stock price target?
Price Target
85.53
EUR
According to Wall Street analysts, the average 1-year price target for BH3 is 85.53 EUR with a low forecast of 59.01 EUR and a high forecast of 117.03 EUR.
What is the Revenue forecast for PTC Therapeutics Inc?
Projected CAGR
-2%
Over the last 13 years, the compound annual growth rate for Revenue has been 35%. The projected CAGR for the next 3 years is -2%.
What is the Gross Profit forecast for PTC Therapeutics Inc?
Projected CAGR
-5%
The compound annual growth rate for Gross Profit over the next 3 years is -5%.
What is the Operating Income forecast for PTC Therapeutics Inc?
Projected CAGR
-12%
The compound annual growth rate for Operating Income over the next 3 years is -12%.
What is the Pre-Tax Income forecast for PTC Therapeutics Inc?
Projected CAGR
-20%
The compound annual growth rate for Pre-Tax Income over the next 3 years is -20%.
What is the Net Income forecast for PTC Therapeutics Inc?
Projected CAGR
-20%
Over the last 13 years, the compound annual growth rate for Net Income has been 70%. The projected CAGR for the next 3 years is -20%.
